Favourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired Stock

Yahoo FinanceApr 20 21:56

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant...

PR NewswireApr 12 04:30

Cadrenal Therapeutics: FDA Grants Orphan Drug Designation For Tecarfarin; Stock Jumps

RTTNewsApr 9 21:24

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients With LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant...

PR NewswireApr 9 21:00

HC Wainwright & Co. Reiterates Buy on Cadrenal Therapeutics, Maintains $3 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cadrenal Therapeutics with a Buy and maintains $3 price target.

Analyst UpgradesMar 14 19:31

Cadrenal Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/14/2024 411.95% HC Wainwright & Co. → $3 Reiterates Buy → Buy 12/18/2023 582.59% Noble Capital Markets

BenzingaMar 14 19:30